RS55006B1 - Nova jedinjenja kao inhibitori diacilglicerol aciltransferaze - Google Patents
Nova jedinjenja kao inhibitori diacilglicerol aciltransferazeInfo
- Publication number
- RS55006B1 RS55006B1 RS20160648A RSP20160648A RS55006B1 RS 55006 B1 RS55006 B1 RS 55006B1 RS 20160648 A RS20160648 A RS 20160648A RS P20160648 A RSP20160648 A RS P20160648A RS 55006 B1 RS55006 B1 RS 55006B1
- Authority
- RS
- Serbia
- Prior art keywords
- amino
- oxazepin
- pyrimido
- indol
- mmol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1452DE2011 | 2011-05-20 | ||
| US201161503728P | 2011-07-01 | 2011-07-01 | |
| PCT/US2012/038523 WO2012162129A1 (en) | 2011-05-20 | 2012-05-18 | Novel compounds as diacylglycerol acyltransferase inhibitors |
| EP12789931.8A EP2710013B1 (en) | 2011-05-20 | 2012-05-18 | Novel compounds as diacylglycerol acyltransferase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS55006B1 true RS55006B1 (sr) | 2016-11-30 |
Family
ID=47217645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160648A RS55006B1 (sr) | 2011-05-20 | 2012-05-18 | Nova jedinjenja kao inhibitori diacilglicerol aciltransferaze |
Country Status (34)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101919080B1 (ko) | 2011-05-20 | 2018-11-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 |
| EP3492474B1 (en) | 2012-11-23 | 2021-08-11 | GlaxoSmithKline LLC | Intermediates used in the production of diacylglycerol acyltransferase inhibitors |
| WO2014081996A1 (en) * | 2012-11-23 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds as diacylglycerol acyltransferase inhibitors |
| US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
| CN103524431B (zh) * | 2013-09-24 | 2016-01-13 | 西安交通大学 | 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用 |
| WO2015049668A1 (en) | 2013-10-03 | 2015-04-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Novel compound as a diacylglycerol acyltransferase inhibitor |
| WO2015049667A1 (en) | 2013-10-03 | 2015-04-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Novel compound as a diacylglycerol acyltransferase inhibitor |
| CN103880757B (zh) * | 2014-04-15 | 2016-02-24 | 上海毕得医药科技有限公司 | 一种5-羟基嘧啶-2-羧酸的合成方法 |
| WO2016181409A1 (en) | 2015-05-11 | 2016-11-17 | Cadila Healthcare Limited | Saroglitazar magnesium for the treatment of chylomicronemia syndrome - |
| WO2017064635A2 (en) | 2015-10-14 | 2017-04-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
| CN105732461A (zh) * | 2016-02-03 | 2016-07-06 | 常州工程职业技术学院 | 5-甲氧基-6-卤代吲哚的制备方法 |
| CN106083707B (zh) * | 2016-06-01 | 2018-10-26 | 温州大学 | 一种非对称杂芳基硫醚的合成方法 |
| CN107619932B (zh) * | 2016-07-15 | 2020-08-07 | 中国科学院上海有机化学研究所 | 一种萃取组合物、萃取体系及其应用 |
| CN107619928B (zh) * | 2016-07-15 | 2020-08-07 | 中国科学院上海有机化学研究所 | 一种萃取组合物、萃取体系及其应用 |
| RU2706655C1 (ru) * | 2019-01-28 | 2019-11-19 | Акционерное общество "Гознак" (АО "Гознак") | Полимерсодержащее композиционное защищенное изделие |
| CN117603242B (zh) * | 2023-11-30 | 2026-08-11 | 沧州普瑞东方科技有限公司 | 一种反式-1-乙氧乙烯基-2-硼酸频那醇酯的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090036425A1 (en) * | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| KR101685718B1 (ko) * | 2008-12-19 | 2016-12-12 | 제넨테크, 인크. | 헤테로시클릭 화합물 및 사용 방법 |
| TW201038580A (en) * | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| JP2012520887A (ja) * | 2009-03-18 | 2012-09-10 | シェーリング コーポレイション | ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物 |
| ES2513915T3 (es) | 2009-04-24 | 2014-10-27 | F. Hoffmann-La Roche Ag | Inhibidores de la tirosina quinasa de Bruton |
| KR101919080B1 (ko) | 2011-05-20 | 2018-11-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 |
| US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
-
2012
- 2012-05-18 KR KR1020137033509A patent/KR101919080B1/ko not_active Expired - Fee Related
- 2012-05-18 PT PT127899318T patent/PT2710013T/pt unknown
- 2012-05-18 DK DK12789931.8T patent/DK2710013T3/en active
- 2012-05-18 SG SG2013085501A patent/SG195044A1/en unknown
- 2012-05-18 LT LTEP12789931.8T patent/LT2710013T/lt unknown
- 2012-05-18 PL PL12789931T patent/PL2710013T3/pl unknown
- 2012-05-18 EA EA201391737A patent/EA023030B1/ru unknown
- 2012-05-18 SI SI201230689A patent/SI2710013T1/sl unknown
- 2012-05-18 CA CA2836669A patent/CA2836669C/en not_active Expired - Fee Related
- 2012-05-18 MY MYPI2013702195A patent/MY184553A/en unknown
- 2012-05-18 BR BR112013029935-5A patent/BR112013029935B1/pt not_active IP Right Cessation
- 2012-05-18 HU HUE12789931A patent/HUE028870T2/en unknown
- 2012-05-18 MX MX2013013566A patent/MX346494B/es active IP Right Grant
- 2012-05-18 CN CN201280035792.5A patent/CN103703009B/zh not_active Expired - Fee Related
- 2012-05-18 EP EP12789931.8A patent/EP2710013B1/en active Active
- 2012-05-18 WO PCT/US2012/038523 patent/WO2012162129A1/en not_active Ceased
- 2012-05-18 ES ES12789931.8T patent/ES2588748T3/es active Active
- 2012-05-18 AU AU2012259044A patent/AU2012259044B2/en not_active Ceased
- 2012-05-18 UA UAA201314878A patent/UA111360C2/uk unknown
- 2012-05-18 US US14/118,976 patent/US8859536B2/en not_active Expired - Fee Related
- 2012-05-18 RS RS20160648A patent/RS55006B1/sr unknown
- 2012-05-18 HR HRP20161089TT patent/HRP20161089T1/hr unknown
- 2012-05-18 PE PE2013002531A patent/PE20141204A1/es active IP Right Grant
- 2012-05-18 PH PH1/2013/502401A patent/PH12013502401A1/en unknown
- 2012-05-18 ME MEP-2016-159A patent/ME02479B/me unknown
- 2012-05-18 JP JP2014511575A patent/JP5844456B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-18 IL IL229488A patent/IL229488A/en active IP Right Grant
- 2013-11-19 ZA ZA2013/08664A patent/ZA201308664B/en unknown
- 2013-11-20 DO DO2013000272A patent/DOP2013000272A/es unknown
- 2013-11-20 CO CO13273126A patent/CO6811855A2/es active IP Right Grant
- 2013-11-20 CR CR20130602A patent/CR20130602A/es unknown
- 2013-12-13 MA MA36566A patent/MA35185B1/fr unknown
-
2014
- 2014-09-05 US US14/478,309 patent/US9040517B2/en not_active Expired - Fee Related
-
2015
- 2015-04-24 US US14/695,206 patent/US9273069B2/en not_active Expired - Fee Related
-
2016
- 2016-01-15 US US14/996,318 patent/US9540400B2/en not_active Expired - Fee Related
- 2016-09-19 CY CY20161100926T patent/CY1118188T1/el unknown
- 2016-09-20 SM SM201600328T patent/SMT201600328B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2710013T3 (en) | New compounds such as diacylglycerol-acyltransferase inhibitors | |
| KR101954044B1 (ko) | 피리돈 및 아자-피리돈 화합물 및 사용 방법 | |
| CN109721620A (zh) | Hpk1抑制剂及其用途 | |
| KR20150002573A (ko) | 벤조티아졸-6-일 아세트산 유도체 및 ｈｉｖ 감염을 치료하기 위한 이의 용도 | |
| BRPI0708615A2 (pt) | compostos de pirazol heterobicìclicos e métodos de uso | |
| MX2015004151A (es) | Inhibidores del factor de diferenciacion de crecimiento-8 (gdf-8). | |
| JP2018521025A (ja) | Ｔｎｆ活性のモジュレーターとしてのベンゾオキサジノン誘導体およびその類似体 | |
| EA029312B1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| IL194832A (en) | History of pyridopyrazine and pharmaceutical preparations | |
| TWI915393B (zh) | 作為雄激素受體調節劑的吲哚化合物 | |
| JP7357932B2 (ja) | Ｃｒｈｒ２拮抗薬としての縮合環状尿素誘導体 | |
| CA3129829A1 (en) | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders | |
| WO2025049994A1 (en) | Compounds and compositions as cbp/p300 degraders and uses thereof | |
| KR20230015404A (ko) | 무스카린성 아세틸콜린 수용체 m5의 경쟁적 억제제 및 비경쟁적 억제제 | |
| TW202214634A (zh) | 雜環化合物及其衍生物 | |
| HK1194738B (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
| WO2024002378A1 (zh) | 一类具有激酶抑制功能的化合物及其制备和应用 | |
| NZ617991B2 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors |